<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614066</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-103</org_study_id>
    <nct_id>NCT02614066</nct_id>
  </id_info>
  <brief_title>A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)</brief_title>
  <acronym>ZUMA-3</acronym>
  <official_title>A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kite, A Gilead Company</source>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and
      efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell
      therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Safety (Incidence of adverse events defined as dose-limiting toxicities (DLT)</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall complete remission rate</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Remission</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Residual Disease Negative Remission Rate</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allogeneic Stem Cell Transplant Rate</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KTE-C19</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Relapsed or refractory B-precursor ALL defined as one of the following:

               -  Primary refractory disease

               -  First relapse if first remission ≤ 12 months

               -  Relapsed or refractory disease after first or later salvage therapy

               -  Relapsed or refractory disease after allogeneic transplant provided subject is at
                  least 100 days from stem cell transplant at the time of enrollment

          2. Morphological disease in the bone marrow (≥ 5% blasts)

          3. Subjects with Ph+ disease are eligible if they are intolerant to tyrosine kinase
             inhibitor (TKI) therapy, or if they have relapsed/refractory disease despite treatment
             with at least 2 different TKIs

          4. Age 18 or older

          5. Eastern cooperative oncology group (ECOG) performance status of 0 or 1

          6. Adequate renal, hepatic, pulmonary and cardiac function defined as:

               -  Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 cc/min

               -  Serum ALT/AST ≤ 2.5 x ULN

               -  Total bilirubin ≤ 1.5 mg/dl, except in subjects with Gilbert's syndrome.

               -  Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion, and no
                  clinically significant arrhythmias

               -  Baseline oxygen saturation &gt; 92% on room air

          7. In subjects previously treated with blinatumomab, CD19 tumor expression in bone marrow
             or peripheral blood.

        Exclusion Criteria:

          1. Diagnosis of Burkitt's leukemia/lymphoma according to WHO classification or chronic
             myelogenous leukemia lymphoid blast crisis

          2. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g.
             cervix, bladder, breast) unless disease free for at least 3 years

          3. Isolated extramedullary disease

          4. CNS abnormalities

               -  Presence of CNS-3 disease or CNS-2 disease with neurological changes

               -  History or presence of any CNS disorder such as a seizure disorder,
                  cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any
                  autoimmune disease with CNS involvement

          5. History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome,
             Shwachman-Diamond syndrome or any other known bone marrow failure syndrome

          6. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or
             other clinically significant cardiac disease within 12 months of enrollment

          7. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of
             enrollment.

          8. Primary immunodeficiency

          9. Known infection with HIV, hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV
             positive).

         10. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or
             requiring IV antimicrobials for management.

         11. Prior medication:

               -  Salvage chemotherapy including TKIs for Ph+ ALL within 1 week prior to enrollment

               -  Prior CD19 directed therapy other than blinatumomab

               -  Treatment with alemtuzumab within 6 months prior to leukapheresis, or treatment
                  with clofarabine or cladribine within 3 months prior to leukapheresis

               -  Donor lymphocyte infusion (DLI) within 28 days prior to enrollment

               -  Any drug used for GVHD within 4 weeks prior to enrollment

               -  At least 3 half-lives must have elapsed from any prior systemic
                  inhibitory/stimulatory immune checkpoint molecule therapy prior to enrollment

               -  Corticosteroid therapy for 7 days prior to enrollment

         12. Presence of any indwelling line or drain (e.g., percutaneous nephrostomy tube,
             indwelling Foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter).
             Ommaya reservoirs and dedicated central venous access catheters such as a Port-a-Cath
             or Hickman catheter are permitted

         13. Acute GVHD grade II-IV by Glucksberg criteria or severity B-D by IBMTR index; acute or
             chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment

         14. Live vaccine ≤ 4 weeks prior to enrollment

         15. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the preparative chemotherapy on the fetus or infant.
             Females who have undergone surgical sterilization or who have been postmenopausal for
             at least 2 years are not considered to be of childbearing potential

         16. Subjects of both genders of child-bearing potential who are not willing to practice
             birth control from the time of consent through 6 months after the completion of
             KTE-C19

         17. In the investigators judgment, the subject is unlikely to complete all
             protocol-required study visits or procedures, including follow-up visits, or comply
             with the study requirements for participation

         18. History of autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus)
             resulting in end organ injury or requiring systemic immunosuppression/systemic disease
             modifying agents within the last 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajul Jain, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>844-454-KITE</phone>
    <email>medinfo@kitepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krisma Montalvo</last_name>
      <phone>858-822-6843</phone>
      <email>kcmontalvo@AD.UCSD.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruck Habtemariam</last_name>
      <email>bhabtemariam@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Farzam Hariri, MD</last_name>
      <phone>310-206-5756</phone>
      <email>FHariri@mednet.ucla.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blake Johnson</last_name>
      <email>blakej@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jinah Chung</last_name>
      <email>jinahec@uci.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jones</last_name>
      <phone>916-734-1093</phone>
      <email>kmjjones@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Cavallone</last_name>
      <phone>415-476-4765</phone>
      <email>Erika.Cavallone@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Johnson</last_name>
      <phone>415-476-4125</phone>
      <email>rachel.johnson@ucsf.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Scott</last_name>
      <phone>813-745-6939</phone>
      <email>Matthew.Scott@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunhee Lee</last_name>
      <email>kunhee.lee@emoryhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Small</last_name>
      <phone>773-702-9440</phone>
      <email>asmall@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ray Robinson</last_name>
      <phone>773-702-2023</phone>
      <email>rrobinson7@medicine.bsd.uchicago.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Jasky</last_name>
      <phone>708-327-3095</phone>
      <email>ejaksy@luc.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Stiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunita Philip</last_name>
      <phone>410-328-8199</phone>
      <email>sphilip1@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Jacobs</last_name>
      <email>Matthew_Jacobs@DFCI.HARVARD.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Allen</last_name>
      <email>VALLEN2@PARTNERS.ORG</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariam Shafiq</last_name>
      <email>Shafiq.mariam@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phil Powell</last_name>
      <phone>314-747-2740</phone>
      <email>charles.powell@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Armin Ghobadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Tisch Cancer Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Carmoody</last_name>
      <phone>212-241-1598</phone>
      <email>Megan.Carmody@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sonia Rau</last_name>
      <email>sonia.rai@mssm.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvette Bernal</last_name>
      <phone>646-888-1370</phone>
      <email>bernaly@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>JaeHong Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Worth</last_name>
      <email>Shawna_worth@URMC.Rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robin Boerman</last_name>
      <email>Robin_Boerman@urmc.rochester.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Cardona</last_name>
      <phone>615-329-7254</phone>
      <email>tiffany.cordona@scresearch.net</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Johnson</last_name>
      <phone>615-329-7355</phone>
      <email>JessicaM.Johnson@scresearch.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Lee</last_name>
      <email>Amber.d.lee@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Goetz</last_name>
      <email>erica.goetz@bswhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Jones</last_name>
      <email>EDJones2@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Bailey</last_name>
      <phone>206-215-1471</phone>
      <email>Neil.Bailey@swedish.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilli Johnson</last_name>
      <phone>206-667-3608</phone>
      <email>Ljjohns3@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Ryan Cassaday, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network - Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Luimes</last_name>
      <email>nicole.luimes@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Andre Schuh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

